Bガタ カンエン カンジャ ニ オケル カクサン アナログセイザイ ニ ヨル ウイルス インセイカ ゴ ノ ケイカ ニ カンスル ケントウ by 宮内, 智夫 & Tomoo, Miyauchi
  【要約】 
 
Efficacy of Lamivudine or Entecavir against Virological 
Rebound after Achieving HBV DNA Negativity in Chronic 
Hepatitis B Patients 
(B 型肝炎患者における核酸アナログ製剤による 
ウイルス陰性化後の経過に関する検討) 
 
 
 
 
 
       千葉大学大学院医学薬学府 
      先端医学薬学専攻 腫瘍内科学 
       （主任：横須賀 收 教授） 
            宮内 智夫 
 
Abstract 
Nucleos(t)ide analogues (NAs) lead to viral suppression and undetectable hepatitis B 
virus (HBV) DNA in some individuals infected with HBV, but the rate of virological 
rebound has been unknown in such patients. We examined the prevalence of virological 
rebound of HBV DNA among NA-treated patients with undetectable HBV DNA. We 
retrospectively analyzed 303 consecutive patients [158 entecavir (ETV)- and 145 
lamivudine (LAM)-treated] who achieved HBV DNA negativity, defined as HBV DNA 
< 3.7 log IU/mL for at least 3 months. They were followed up and their features, 
including their rates of viral breakthrough, were determined. Viral rebound after HBV 
DNA negativity was not observed in the ETV-group. Viral rebound after HBV DNA 
negativity occurred in 38.7% of 62 HBe antigen-positive patients in the LAM-group. 
On multivariate analysis, age was an independent factor for viral breakthrough among 
these patients (P = 0.035). Viral rebound after HBV DNA negativity occurred in 29.1% 
of 79 HBe antigen-negative patients in the LAM-group. Differently from LAM, ETV 
could inhibit HBV replication once HBV DNA negativity was achieved. In contrast, 
LAM could not inhibit HBV replication even if HBV negativity was achieved in the 
early phase. Attention should be paid to these features in clinical practice. 
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